Connect Biopharma Holdings Limited

What they do

Connect Biopharma is a clinical-stage biopharmaceutical company focused on developing rademikibart, a human monoclonal IgG4 antibody targeting IL-4R, for the treatment of asthma and COPD. The company is conducting Phase 2 studies for acute exacerbations and has a license agreement with Simcere for Greater China rights. It has no approved products and generates revenue primarily from collaboration and milestone payments.

Revenue drivers

• Simcere license agreement — License and collaboration revenues from Simcere, which has exclusive rights to develop and commercialize rademikibart in Greater China. For Q2 2026, revenue was $2.8 million, primarily from a regulatory milestone, with remaining potential milestones of up to approximately $99 million.
• Cost reimbursements for clinical materials — Revenues from cost reimbursements under the Simcere agreement were $48,000 for both Q2 and H1 2025, representing a minor revenue source.
• No product sales — The company has no approved products, so product sales are currently zero. Annual revenue was $26.0 million in 2024, largely from milestones, but fell to $64,000 in 2025.

Recent performance

For Q2 2026, the company reported revenue of $2.8 million, up from $16,000 in Q1 2026, and $48,000 in Q2 2025. Net loss for 2025 was $55.5 million, worsening from $15.6 million in 2024. Research and development expenses for Q2 2026 were $16.3 million, up from $8.8 million in Q2 2025, due to the Phase 2 Seabreeze STAT studies. Cash and equivalents were $27.0 million as of June 30, 2026, while total assets were $43.5 million and total liabilities $16.6 million.

Strategy

The company is advancing rademikibart through Phase 2 Seabreeze STAT studies for acute asthma and COPD exacerbations, with topline data expected in September 2026. It plans to meet with the FDA to align on a Phase 3 program after data readouts. Additionally, it initiated an open-label Phase 2 Seabreeze STAT IV study to evaluate IV administration, bridging from 600 mg subcutaneous to 300 mg IV push. The company aims to leverage potential healthcare cost savings and chronic use if approved.

Risks

• Clinical development risk — Phase 2 outcomes are uncertain and may not support Phase 3 or regulatory approval, as early-stage results may not be indicative of later-stage success.
• Cash burn and funding risk — Operating cash flow was negative $51.2 million in 2025, and cash of $27.0 million may be insufficient to fund all planned development without additional financing.
• Regulatory approval uncertainty — The company has no approved products; rademikibart must gain FDA alignment and approval, which is a lengthy and uncertain process.
• Reliance on collaboration partner — Revenue depends on the Simcere license agreement, and the timing of future milestones is uncertain, as is the partner's execution.

Outlook

Management expects to report topline results from both Phase 2 Seabreeze STAT studies in September 2026, which will inform a potential Phase 3 endpoint and sample size. Following the results, they plan to meet with the FDA to align on a Phase 3 program. Cash runway is expected to last at least one year from August 12, 2026, based on the current operating plan.